Schizophrenia Clinical Trial
Official title:
Emotional Intelligence in Schizophrenia and Bipolar I Disorder: a Comparison Between Patients, Their Siblings, and Healthy Controls
Scientific Background
Emotional Intelligence (EI) as a part of social cognition is a rather new area of interest
which focuses on personality traits and abilities enabling people to cope with both their own
feelings as well as those of others. The "Mayer-Salovey-Caruso-Emotional-Intelligence-Test"
(MSCEIT) (1) represents a valid and reliable instrument which exclusively covers the
emotional components of social cognition. Recent findings indicate, that social cognitive
impairments are useful vulnerability indicators and that EI could be an endophenotype for
schizophrenia and bipolar I disorder (BD I). To confirm the endophenotype theory, studies
concerning EI in relatives of schizophrenia and bipolar patients are needed. To date, studies
on EI in BD patients as well as in first degree relatives of patients with schizophrenia or
BD haven`t been conducted yet. Accordingly, the current study focuses on the four categories
assessed by the MSCEIT and aims to compare the task performance of patients, their first
degree relatives and healthy control subjects. We assume that the task performance of
relatives lies between that of patients and controls. The confirmation of this assumption
would verify the trait marker hypothesis and could be a next step to identify a heritable
endophenotype for schizophrenia and BD.
Hypotheses
Compared to healthy control subjects patients suffering from schizophrenia or BD I show
deficits in EI. Siblings of patients with schizophrenia or BD I show deficits in EI and their
task performance lies between that of patients and healthy controls. Deficits in EI are more
pronounced in schizophrenia patients than in patients with BD I and are more pronounced in
siblings of schizophrenia patients than in siblings of patients with BD I. Independently of
diagnosis, deficits in EI affect patients' functional and subjective outcomes.
Methods
Emotional Intelligence will be examined using the MSCEIT in patients with schizophrenia,
siblings of schizophrenia patients, patients with BD I, siblings of BD I patients and healthy
volunteers matched for age, sex, and educational level. Structured clinical interviews
according to DSM-IV (M.I.N.I. + SCID II) will be carried out to assure the diagnosis of
schizophrenia or bipolar disorder as well as to detect (comorbid) Axis I and Axis II
psychiatric disorders (patients, siblings, control subjects). Functional outcome will be
assessed by using the GAF (Global Assessment of Functioning Scale) and the PSP (Personal and
Social Performance Scale), subjective quality of life will be examined using the BELP
(Berliner Lebensqualiätsprofil). The MWT-B (Multiple choice vocabulary test) will be used to
assess premorbid intelligence.
n/a
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05039489 -
A Study on the Brain Mechanism of cTBS in Improving Medication-resistant Auditory Hallucinations in Schizophrenia
|
N/A | |
Completed |
NCT05321602 -
Study to Evaluate the PK Profiles of LY03010 in Patients With Schizophrenia or Schizoaffective Disorder
|
Phase 1 | |
Completed |
NCT05111548 -
Brain Stimulation and Cognitive Training - Efficacy
|
N/A | |
Completed |
NCT04503954 -
Efficacy of Chronic Disease Self-management Program in People With Schizophrenia
|
N/A | |
Completed |
NCT02831231 -
Pilot Study Comparing Effects of Xanomeline Alone to Xanomeline Plus Trospium
|
Phase 1 | |
Completed |
NCT05517460 -
The Efficacy of Auricular Acupressure on Improving Constipation Among Residents in Community Rehabilitation Center
|
N/A | |
Completed |
NCT03652974 -
Disturbance of Plasma Cytokine Parameters in Clozapine-Resistant Treatment-Refractory Schizophrenia (CTRS) and Their Association With Combination Therapy
|
Phase 4 | |
Recruiting |
NCT04012684 -
rTMS on Mismatch Negativity of Schizophrenia
|
N/A | |
Recruiting |
NCT04481217 -
Cognitive Factors Mediating the Relationship Between Childhood Trauma and Auditory Hallucinations in Schizophrenia
|
N/A | |
Completed |
NCT00212784 -
Efficacy and Safety of Asenapine Using an Active Control in Subjects With Schizophrenia or Schizoaffective Disorder (25517)(P05935)
|
Phase 3 | |
Completed |
NCT04092686 -
A Clinical Trial That Will Study the Efficacy and Safety of an Investigational Drug in Acutely Psychotic People With Schizophrenia
|
Phase 3 | |
Completed |
NCT01914393 -
Pediatric Open-Label Extension Study
|
Phase 3 | |
Recruiting |
NCT03790345 -
Vitamin B6 and B12 in the Treatment of Movement Disorders Induced by Antipsychotics
|
Phase 2/Phase 3 | |
Recruiting |
NCT05956327 -
Insight Into Hippocampal Neuroplasticity in Schizophrenia by Investigating Molecular Pathways During Physical Training
|
N/A | |
Terminated |
NCT03261817 -
A Controlled Study With Remote Web-based Adapted Physical Activity (e-APA) in Psychotic Disorders
|
N/A | |
Terminated |
NCT03209778 -
Involuntary Memories Investigation in Schizophrenia
|
N/A | |
Completed |
NCT02905604 -
Magnetic Stimulation of the Brain in Schizophrenia or Depression
|
N/A | |
Recruiting |
NCT05542212 -
Intra-cortical Inhibition and Cognitive Deficits in Schizophrenia
|
N/A | |
Completed |
NCT04411979 -
Effects of 12 Weeks Walking on Cognitive Function in Schizophrenia
|
N/A | |
Terminated |
NCT03220438 -
TMS Enhancement of Visual Plasticity in Schizophrenia
|
N/A |